New details about DRAxIMAGE® MAA – 27 November 2019

- From 1 December 2019, the price of DRAxIMAGE® MAA will be $1,045.00 per pack of 10 vials for all Australian customers.

- This comes after consultation with the Australian nuclear medicine community and a complete review of the MAA supply chain.

- ANSTO will also continue to advocate towards market normalization of MAA through supporting the Marketing Authorisation processes for this product.

As of 1 August 2019, ANSTO became the sole provider of DRAxIMAGE® MAA (MAA) via a Section 19A approval under the Therapeutic Goods Act. ANSTO distributes MAA to Australian customers.

Feedback from customers and the wider nuclear medicine community was that the cost of $1,711.14 which was set to reflect ANSTO’s supply chain, needed to be refined.

In response, over the past months, ANSTO has met stakeholders from across the nuclear medicine community to understand the opportunities to improve how this product is accessed in the Australian market.

Following this consultation and a full review of the supply chain, ANSTO has successfully achieved a competitive review of our access to MAA. All changes will be passed onto Australian customers from 1 December.

ANSTO will continue to work with all stakeholders to achieve market normalization for the supply of MAA in Australia through the introduction of a registered product.

For more information please contact ANSTO Customer Service on 1800 251 572